Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

castle biosciences inc - CSTL

CSTL

Close Chg Chg %
25.35 -0.08 -0.32%

Closed Market

25.27

-0.08 (0.32%)

Volume: 280.89K

Last Updated:

Mar 25, 2026, 4:00 PM EDT

Trade Now

Company Overview: castle biosciences inc - CSTL

CSTL Key Data

Open

$25.81

 Day Range

25.08 - 26.19

52 Week Range

14.59 - 44.28

 Market Cap

$753.69M

Shares Outstanding

29.73M

 Public Float

28.94M

Beta

1.09

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.84

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

402.45K

  

CSTL Performance

1 Week
 
 1.08%
 
1 Month
 
 -14.54%
 
3 Months
 
 -35.85%
 
1 Year
 
 26.73%
 
5 Years
 
 -57.86%
 

CSTL Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 8
Full Ratings ➔

About castle biosciences inc - CSTL

Castle Biosciences, Inc.is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, barrett’s esophagus, uveal melanoma, and in the treatment of mental health conditions. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.

CSTL At a Glance

Castle Biosciences, Inc.
1500 West Parkwood Avenue
Friendswood, Texas 77546
Phone 1-866-788-9007 Revenue 344.23M
Industry Medical Specialties Net Income -24,158,000.00
Sector Health Technology 2025 Sales Growth 3.662%
Fiscal Year-end 12 / 2026 Employees 883
View SEC Filings

CSTL Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 3.276
Price to Book Ratio 2.452
Price to Cash Flow Ratio 17.52
Enterprise Value to EBITDA -424.26
Enterprise Value to Sales 2.513
Total Debt to Enterprise Value 0.043

CSTL Efficiency

Revenue/Employee 389,840.317
Income Per Employee -27,359.003
Receivables Turnover 7.935
Total Asset Turnover 0.592

CSTL Liquidity

Current Ratio 5.258
Quick Ratio 5.109
Cash Ratio 4.361

CSTL Profitability

Gross Margin 68.66
Operating Margin -12.436
Pretax Margin -8.574
Net Margin -7.018
Return on Assets -4.154
Return on Equity -5.214
Return on Total Capital -4.757
Return on Invested Capital -4.899

CSTL Capital Structure

Total Debt to Total Equity 7.861
Total Debt to Total Capital 7.288
Total Debt to Total Assets 6.076
Long-Term Debt to Equity 7.469
Long-Term Debt to Total Capital 6.925
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Castle Biosciences Inc - CSTL

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
137.04M 219.79M 332.07M 344.23M
Sales Growth
+45.65% +60.38% +51.09% +3.66%
Cost of Goods Sold (COGS) incl D&A
41.68M 55.55M 73.25M 107.88M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
10.54M 12.33M 16.00M 40.77M
Depreciation
2.28M 3.32M 4.89M 5.93M
Amortization of Intangibles
8.27M 9.01M 11.11M 34.84M
COGS Growth
+122.27% +33.29% +31.86% +47.28%
Gross Income
95.36M 164.23M 258.82M 236.35M
Gross Income Growth
+26.58% +72.22% +57.59% -8.68%
Gross Profit Margin
+69.59% +74.72% +77.94% +68.66%
2022 2023 2024 2025 5-year trend
SG&A Expense
186.50M 232.21M 250.15M 279.16M
Research & Development
44.57M 53.29M 51.69M 51.49M
Other SG&A
141.94M 178.92M 198.46M 227.66M
SGA Growth
+61.59% +24.51% +7.72% +11.60%
Other Operating Expense
- - - -
-
Unusual Expense
- (18.29M) (555.00K) (982.00K)
EBIT after Unusual Expense
(72.85M) (67.98M) 9.22M (41.83M)
Non Operating Income/Expense
3.97M 10.62M 12.92M 12.40M
Non-Operating Interest Income
3.97M 10.62M 12.92M 11.77M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
17.00K 11.00K 577.00K 86.00K
Interest Expense Growth
+1,600.00% -35.29% +5,145.45% -85.10%
Gross Interest Expense
17.00K 11.00K 577.00K 86.00K
Interest Capitalized
- - - -
-
Pretax Income
(68.90M) (57.37M) 21.56M (29.51M)
Pretax Income Growth
-72.21% +16.75% +137.59% -236.87%
Pretax Margin
-50.28% -26.10% +6.49% -8.57%
Income Tax
(1.77M) 101.00K 3.32M (5.36M)
Income Tax - Current - Domestic
111.00K 324.00K 1.92M 872.00K
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(1.88M) (223.00K) 1.40M (6.23M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(67.14M) (57.47M) 18.25M (24.16M)
Minority Interest Expense
- - - -
-
Net Income
(67.14M) (57.47M) 18.25M (24.16M)
Net Income Growth
-114.55% +14.41% +131.75% -232.41%
Net Margin Growth
-48.99% -26.15% +5.49% -7.02%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(67.14M) (57.47M) 18.25M (24.16M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(67.14M) (57.47M) 18.25M (24.16M)
EPS (Basic)
-2.5769 -2.1441 0.6569 -0.8334
EPS (Basic) Growth
-107.00% +16.80% +130.64% -226.87%
Basic Shares Outstanding
26.05M 26.80M 27.78M 28.99M
EPS (Diluted)
-2.5769 -2.1441 0.6236 -0.8334
EPS (Diluted) Growth
-107.00% +16.80% +129.08% -233.64%
Diluted Shares Outstanding
26.05M 26.80M 29.25M 28.99M
EBITDA
(80.60M) (55.65M) 24.67M (2.04M)
EBITDA Growth
-119.78% +30.96% +144.33% -108.27%
EBITDA Margin
-58.81% -25.32% +7.43% -0.59%

Snapshot

Average Recommendation BUY Average Target Price 48.50
Number of Ratings 8 Current Quarters Estimate -0.49
FY Report Date 03 / 2026 Current Year's Estimate -1.175
Last Quarter’s Earnings -0.08 Median PE on CY Estimate N/A
Year Ago Earnings -0.83 Next Fiscal Year Estimate -0.544
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 8 8 8 8
Mean Estimate -0.49 -0.31 -1.18 -0.54
High Estimates -0.29 -0.24 -0.79 -0.18
Low Estimate -0.58 -0.38 -1.43 -0.85
Coefficient of Variance -23.24 -18.78 -22.70 -51.49

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 7 7 7
OVERWEIGHT 1 1 1
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Insider Actions for Castle Biosciences Inc - CSTL

Date Name Shares Transaction Value
Mar 10, 2026 G. Bradley Cole Director 26,712 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $3.38 per share 90,286.56
Mar 10, 2026 G. Bradley Cole Director 21,964 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $28.44 per share 624,656.16
Mar 10, 2026 G. Bradley Cole Director 19,309 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $28.51 per share 550,499.59
Mar 10, 2026 G. Bradley Cole Director 20,000 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 10, 2026 Franklin Michael Stokes Chief Financial Officer 60,085 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $27.98 per share 1,681,178.30
Jan 23, 2026 Derek J. Maetzold Pres. & Chief Exec. Officer; Director 87,715 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $40.01 per share 3,509,477.15
Aug 13, 2025 Derek J. Maetzold Pres. & Chief Exec. Officer; Director 112,702 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $19.36 per share 2,181,910.72
Aug 13, 2025 Derek J. Maetzold Pres. & Chief Exec. Officer; Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 13, 2025 Franklin Michael Stokes Chief Financial Officer 48,716 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $19.36 per share 943,141.76
Aug 13, 2025 Franklin Michael Stokes Chief Financial Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 13, 2025 Tobin W. Juvenal Chief Commercial Officer 88,821 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 13, 2025 Tobin W. Juvenal Chief Commercial Officer 84,527 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $19.36 per share 1,636,442.72
Aug 13, 2025 Tobin W. Juvenal Chief Commercial Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 13, 2025 Kristen M. Oelschlager Chief Operating Officer 174,604 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Aug 13, 2025 Kristen M. Oelschlager Chief Operating Officer 171,800 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $19.36 per share 3,326,048.00
Aug 13, 2025 Kristen M. Oelschlager Chief Operating Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Castle Biosciences Inc in the News